|
시장보고서
상품코드
2049580
Drug Discovery 정보학 시장 보고서 : 워크플로우별, 기능별, 방법별, 최종사용자별, 지역별(2026-2034년)Drug Discovery Informatics Market Report by Workflow, Function, Mode, End User (Pharmaceutical Companies, Biotechnology Companies, Contract Research Organization, and Others), and Region 2026-2034 |
||||||
세계의 Drug Discovery 정보학 시장 규모는 2025년에 39억 7,000만 달러에 달했습니다. 향후 IMARC Group은 2034년까지 시장 규모가 84억 4,000만 달러에 달하고, 2026년부터 2034년까지 CAGR 8.48%로 성장할 것으로 예측했습니다.
Drug Discovery 정보학은 대량의 생화학 데이터를 분석 및 해석하기 위해 사용되는 기술 솔루션입니다. 이 데이터는 연구 목적으로 임상 실험실에서 수행되는 실험에서 생성되며, 다양한 의약품 개발에 대한 지식을 얻기 위해 활용됩니다. 여기에는 시퀀싱, 타겟 데이터 분석, 데이터 시각화, 도킹, 분자 모델링, 신약 개발을 위한 데이터베이스 보호 등 다양한 소프트웨어 및 하드웨어 기반 도구가 포함됩니다. 그 결과, 헬스케어 기관, 제약 및 바이오테크놀러지 기업, 의약품 개발 수탁기관(CRO)에서 널리 활용되고 있습니다.
세계 헬스케어 및 제약 산업의 괄목할만한 성장은 이 시장의 전망을 밝게 하는 주요 요인 중 하나입니다. 또한, 만성 질환의 유병률 증가와 희귀 질환을 치료할 수 있는 효과적인 솔루션에 대한 수요 증가도 시장 성장을 촉진하고 있습니다. Drug Discovery 정보학은 신약 후보물질의 분석과 여러 출처의 생물학적 정보 처리를 위해 제약기업에서 널리 활용되고 있습니다. 또한, 모델링 및 시뮬레이션을 통해 약동학 결과를 예측하는 데 도움이 되는 혁신적인 생리적 약동학(PBPK) 시뮬레이터 플랫폼의 개발 등 다양한 기술 발전도 시장 성장을 촉진하는 요인으로 작용하고 있습니다. 이에 따라 희귀질환 치료제(희귀의약품) 개발을 위한 정부 및 민간 의료기관의 투자 증가도 시장 성장에 기여하고 있습니다. 고령화, 바이오인포매틱스 분야의 광범위한 연구개발(R&D) 활동 등 다른 요인들도 시장을 더욱 견인할 것으로 예상됩니다.
본 보고서에서 답변하는 주요 질문
- 세계 Drug Discovery 정보학 시장은 지금까지 어떻게 성장해 왔으며, 향후 몇 년 동안 어떻게 변화할 것인가?
- COVID-19는 세계 Drug Discovery 정보학 시장에 어떤 영향을 미쳤는가?
- 주요 지역 시장은 어디인가?
- 워크플로우를 기반으로 한 시장 분석은 어떠한가?
- 기능별 시장 분석은 어떻게 이루어지고 있는가?
- 제공 형태별 시장 현황은 어떠한가?
- 최종사용자별 시장 분석은 어떻게 이루어지고 있는가?
- 이 산업의 밸류체인에서 각 단계는 무엇인가?
- 이 산업의 주요 촉진요인과 과제는 무엇인가?
- 세계 Drug Discovery 정보학 시장의 구조는 무엇이며, 주요 플레이어는 누구인가?
- 이 업계의 경쟁은 얼마나 치열한가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 Drug Discovery 정보학 시장
제6장 시장 내역 : 워크플로우별
제7장 시장 내역 : 기능별
제8장 시장 내역 : 모드별
제9장 시장 내역 : 최종사용자별
제10장 시장 내역 : 지역별
제11장 SWOT 분석
제12장 밸류체인 분석
제13장 Porter's Five Forces 분석
제14장 가격 분석
제15장 경쟁 구도
KSM 26.06.10The global drug discovery informatics market size reached USD 3.97 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 8.44 Billion by 2034, exhibiting a growth rate (CAGR) of 8.48% during 2026-2034.
Drug discovery informatics is a technological solution used for analyzing and interpreting large volumes of biochemical data. The data is generated from the experiments conducted in clinical laboratories for research purposes and utilized for generating insights regarding the development of various drugs. It involves numerous software and hardware-based tools for sequencing, target data analysis, data visualization, docking, molecular modelling, database protection for drug discovery and development. As a result, it is widely used by healthcare institutions, pharmaceutical and biotechnology organizations and contract research organizations (CROs).
Significant growth in the healthcare and pharmaceutical industries across the globe represents one of key the factors creating a positive outlook for the market. Furthermore, the increasing prevalence of chronic medical disorders and the escalating requirement for effective solutions to treat rare diseases are also augmenting the market growth. Drug discovery informatics is widely used by pharmaceutical organizations for the analysis of new drug entities and handling of the biological information from multiple sources. Additionally, various technological advancements, such as the development of innovative Physiologically-based Pharmacokinetic (PBPK) Simulator platforms, which aid in predicting pharmacokinetic outcomes through modeling and simulation, are acting as other growth-inducing factors. In line with this, increasing investments by government and private healthcare institutions to develop orphan drugs is also contributing to the market growth. Other factors, including the rising geriatric population, along with extensive research and development (R&D) activities in the field of bioinformatics, are anticipated to drive the market further.
KEY MARKET SEGMENTATION:
Breakup by Workflow:
- Drug Discovery
- Drug Development
Breakup by Function:
- Sequence Analysis Platforms
- Molecular Modelling
- Molecular Docking
- Clinical Trial Data Management
- Others
Breakup by Mode:
- Outsourced
- In-house
Breakup by End User:
- Pharmaceutical Companies
- Biotechnology Companies
- Contract Research Organization (CROs)
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
COMPETITIVE LANDSCAPE:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Accenture Plc, Certara, Charles River Laboratories Inc., Collaborative Drug Discovery Inc., Eurofins DiscoverX Products, Infosys Ltd., International Business Machines Corporation, Jubilant Biosys Limited, Oracle Corporation, PerkinElmer Inc., Selvita and Thermo Fisher Scientific Inc.
KEY QUESTIONS ANSWERED IN THIS REPORT
- How has the global drug discovery informatics market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global drug discovery informatics market?
- What are the key regional markets?
- What is the breakup of the market based on the workflow?
- What is the breakup of the market based on the function?
- What is the breakup of the market based on the mode?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global drug discovery informatics market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Drug Discovery Informatics Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Workflow
- 6.1 Drug Discovery
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Drug Development
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Function
- 7.1 Sequence Analysis Platforms
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Molecular Modelling
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Molecular Docking
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Clinical Trial Data Management
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
8 Market Breakup by Mode
- 8.1 Outsourced
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 In-house
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
9 Market Breakup by End User
- 9.1 Pharmaceutical Companies
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Biotechnology Companies
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Contract Research Organization (CROs)
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
- 9.4 Others
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.1.1 United States
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.2.1 China
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.3.1 Germany
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.4.1 Brazil
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Accenture PLC
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 Certara
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.3 Charles River Laboratories Inc.
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 Collaborative Drug Discovery Inc.
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.5 Eurofins DiscoverX Products
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.6 Infosys Ltd.
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.6.4 SWOT Analysis
- 15.3.7 International Business Machines Corporation
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.7.4 SWOT Analysis
- 15.3.8 Jubilant Biosys Limited
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.9 Oracle Corporation
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 PerkinElmer Inc.
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis
- 15.3.11 Selvita
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.12 Thermo Fisher Scientific Inc.
- 15.3.12.1 Company Overview
- 15.3.12.2 Product Portfolio
- 15.3.12.3 Financials
- 15.3.12.4 SWOT Analysis
- 15.3.1 Accenture PLC
